The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Signatures of mutational processes in human cancer
Open accessAbstract
All cancers are caused by somatic mutations; however, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single cancer class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, 'kataegis', is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer, with potential implications for understanding of cancer aetiology, prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of TAA-derived epitopes has the advantage of allowing development of an off-the-shelf product for a tumour indication with low mutational burden such as GBM, where patients’ tumours express only few tumour-specific antigens [38].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“In MM, SBS9, associated with mutations introduced by polymerase η repair of activation-induced deaminase (AID) activity26,31,32, was strongly linked with Q61H”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [26]
In the citing paper
“Five substitution and five rearrangement signatures [8, 9] were identified”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [8]
In the citing paper
“a high SNV burden associated with APOBEC substitution signature [8]”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [8]
In the citing paper
“It has also been noted that the 'pol h mutational signature' (Signature 9; http://cancer.sanger.ac.uk/cosmic/sig natures) occurs in chronic lymphocytic leukemia and malignant Bcell lymphoma genomes 6,26,27 .”
From DNA polymerase η mutational signatures are found in a variety of different types of cancer (2018) · cites this paper as [6]
In the citing paper
“Several distinct mutational signatures sculpt the genome of NSCLC – including signatures of tobacco exposure and APOBEC-mediated cytidine deamination57.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [57]
In the citing paper
“Melanoma somatic mutations consist almost entirely of C → T transitions, 28% of which are TCC → T mutations (19,31).”
From Evidence for recent, population-specific evolution of the human mutation rate (2015) · cites this paper as [19]
In the citing paper
“Excess C → T transitions are characteristic of several different mutagenic processes including UV damage and cytosine deamination (19).”
From Evidence for recent, population-specific evolution of the human mutation rate (2015) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationStratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
Self-citationSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Self-citationThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,100 of 1,100
Derer, A., Frey, B., Fietkau, R., & Gaipl, U. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1771-8 · Cited by 155
Rapid and dynamic transcriptome regulation by RNA editing and RNA modifications
Licht, K., & Jantsch, M. F. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201511041 · Cited by 154
UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer
Liu-Smith, F., Jia, J., & Zheng, Y. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-56017-5_3 · Cited by 147
Mutational signature distribution varies with DNA replication timing and strand asymmetry
Tomkova, M., Tomek, J., Kriaucionis, S., & Schuster-Böckler, B. (2018) · Genome Biology · doi:10.1186/s13059-018-1509-y · Cited by 137
Prioritization of neurodevelopmental disease genes by discovery of new mutations
Hoischen, A., Krumm, N., & Eichler, E. E. (2014) · Nature Neuroscience · doi:10.1038/nn.3703 · Cited by 149
Migliorini, D., Dutoit, V., Allard, M., Grandjean Hallez, N., Marinari, E., Widmer, V., Philippin, G., Corlazzoli, F., Gustave, R., Kreutzfeldt, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz040 · Cited by 147
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Chuckran, C. A., Liu, C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000967 · Cited by 147
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144
Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J. H., Balasubramanian, G. P., Kleinheinz, K., Toprak, U. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07041-z · Cited by 132
Self-citationImmunocytokines are a promising immunotherapeutic approach against glioblastoma
Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2311 · Cited by 133
Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue
Shi, J., Marconett, C. N., Duan, J., Hyland, P. L., Li, P., Wang, Z., Wheeler, W., Zhou, B., Campan, M., Lee, D. S., et al. (2014) · Nature Communications · doi:10.1038/ncomms4365 · Cited by 137
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
Poetsch, A. R., Boulton, S. J., & Luscombe, N. M. (2018) · Genome Biology · doi:10.1186/s13059-018-1582-2 · Cited by 132
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
Gardner, H. L., Sivaprakasam, K., Briones, N., Zismann, V., Perdigones, N., Drenner, K., Facista, S., Richholt, R., Liang, W., Aldrich, J., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0487-2 · Cited by 120
The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
Weigelt, B., Bi, R., Kumar, R., Blecua, P., Mandelker, D. L., Geyer, F. C., Pareja, F., James, P. A., kConFab Investigators, Couch, F. J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy028 · Cited by 128
Self-citationPrecancerous neoplastic cells can move through the pancreatic ductal system
Makohon-Moore, A. P., Matsukuma, K., Zhang, M., Reiter, J. G., Gerold, J. M., Jiao, Y., Sikkema, L., Attiyeh, M. A., Yachida, S., Sandone, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0481-8 · Cited by 120
Subgroup-specific immune and stromal microenvironment in medulloblastoma
Bockmayr, M., Mohme, M., Klauschen, F., Winkler, B., Budczies, J., Rutkowski, S., & Schüller, U. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1462430 · Cited by 121
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Self-citationCombination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Chen, T.-W., Lee, C.-C., Liu, H., Wu, C.-S., Pickering, C. R., Huang, P.-J., Wang, J., Chang, I. Y.-F., Yeh, Y.-M., Chen, C.-D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00493-9 · Cited by 115
Oxidative stress and antioxidants in the pathophysiology of malignant melanoma
Obrador, E., Liu-Smith, F., Dellinger, R. W., Salvador, R., Meyskens, F. L., & Estrela, J. M. (2019) · Biological Chemistry · doi:10.1515/hsz-2018-0327 · Cited by 119
Germline MC1R status influences somatic mutation burden in melanoma
Robles-Espinoza, C. D., Roberts, N. D., Chen, S., Leacy, F. P., Alexandrov, L. B., Pornputtapong, N., Halaban, R., Krauthammer, M., Cui, R., Timothy Bishop, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12064 · Cited by 124
Self-citationPóti, Á., Gyergyák, H., Németh, E., Rusz, O., Tóth, S., Kovácsházi, C., Chen, D., Szikriszt, B., Spisák, S., Takeda, S., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1867-0 · Cited by 116
Self-citationThe mutational impact of culturing human pluripotent and adult stem cells
Kuijk, E., Jager, M., van der Roest, B., Locati, M. D., Van Hoeck, A., Korzelius, J., Janssen, R., Besselink, N., Boymans, S., van Boxtel, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16323-4 · Cited by 124
Pich, O., Muiños, F., Sabarinathan, R., Reyes-Salazar, I., Gonzalez-Perez, A., & Lopez-Bigas, N. (2018) · Cell · doi:10.1016/j.cell.2018.10.004 · Cited by 123
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome
Barrett, M., Hand, C. K., Shanahan, F., Murphy, T., & O’Toole, P. W. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.019 · Cited by 108
Portrait of a cancer: mutational signature analyses for cancer diagnostics
Van Hoeck, A., Tjoonk, N. H., van Boxtel, R., & Cuppen, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5677-2 · Cited by 107
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity
Lamble, A. J., & Lind, E. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00213 · Cited by 119
Brazhnik, K., Sun, S., Alani, O., Kinkhabwala, M., Wolkoff, A. W., Maslov, A. Y., Dong, X., & Vijg, J. (2020) · Science Advances · doi:10.1126/sciadv.aax2659 · Cited by 114
Somatic Mutagenesis in Mammals and Its Implications for Human Disease and Aging
Zhang, L., & Vijg, J. (2018) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031501 · Cited by 108
Luquette, L. J., Miller, M. B., Zhou, Z., Bohrson, C. L., Zhao, Y., Jin, H., Gulhan, D., Ganz, J., Bizzotto, S., Kirkham, S., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01180-2 · Cited by 108
Integrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
Nones, K., Johnson, J., Newell, F., Patch, A. M., Thorne, H., Kazakoff, S. H., de Luca, X. M., Parsons, M. T., Ferguson, K., Reid, L. E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz132 · Cited by 93
“Five substitution and five rearrangement signatures [8, 9] were identified (Figure 2; supplementary Figure S3, available at Annals of Oncology online).”
BackgroundSelf-citationThe circular RNome of primary breast cancer
Smid, M., Wilting, S. M., Uhr, K., Rodríguez-González, F. G., de Weerd, V., Prager-Van der Smissen, W. J. C., van der Vlugt-Daane, M., van Galen, A., Nik-Zainal, S., Butler, A., et al. (2019) · Genome Research · doi:10.1101/gr.238121.118 · Cited by 105
Self-citationTruong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Targeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Davies, H., Morganella, S., Purdie, C. A., Jang, S. J., Borgen, E., Russnes, H., Glodzik, D., Zou, X., Viari, A., Richardson, A. L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1083 · Cited by 99
Self-citationPoulos, R. C., Olivier, J., & Wong, J. W. H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx463 · Cited by 93
Genomic landscape of rat strain and substrain variation
Hermsen, R., de Ligt, J., Spee, W., Blokzijl, F., Schäfer, S., Adami, E., Boymans, S., Flink, S., van Boxtel, R., van der Weide, R. H., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1594-1 · Cited by 93
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Lee, T.-Y., Huang, K.-Y., Chuang, C.-H., Lee, C.-Y., & Chang, T.-H. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107277 · Cited by 95
Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95
The Impact of Environmental and Endogenous Damage on Somatic Mutation Load in Human Skin Fibroblasts
Saini, N., Roberts, S. A., Klimczak, L. J., Chan, K., Grimm, S. A., Dai, S., Fargo, D. C., Boyer, J. C., Kaufmann, W. K., Taylor, J. A., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006385 · Cited by 94
Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation
Ronchi, C. L., Di Dalmazi, G., Faillot, S., Sbiera, S., Assié, G., Weigand, I., Calebiro, D., Schwarzmayr, T., Appenzeller, S., Rubin, B., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1586 · Cited by 93
Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology
Guo, S.-W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz047 · Cited by 96
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95
Self-citationCancer Progress and Priorities: Childhood Cancer
Lupo, P. J., & Spector, L. G. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0941 · Cited by 91
Next-generation DNA damage sequencing
Mingard, C., Wu, J., McKeague, M., & Sturla, S. J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00647e · Cited by 92
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
Glodzik, D., Morganella, S., Davies, H., Simpson, P. T., Li, Y., Zou, X., Diez-Perez, J., Staaf, J., Alexandrov, L. B., Smid, M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3771 · Cited by 84
Self-citationGenome-wide mapping of somatic mutation rates uncovers drivers of cancer
Sherman, M. A., Yaari, A. U., Priebe, O., Dietlein, F., Loh, P.-R., & Berger, B. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01353-8 · Cited by 80
McAdam, E., Brem, R., & Karran, P. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0053 · Cited by 86
Molecular mechanisms and genomic maps of DNA excision repair in Escherichia coli and humans
Hu, J., Selby, C. P., Adar, S., Adebali, O., & Sancar, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.807453 · Cited by 81
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84
High prevalence of focal and multi-focal somatic genetic variants in the human brain
Keogh, M. J., Wei, W., Aryaman, J., Walker, L., van den Ameele, J., Coxhead, J., Wilson, I., Bashton, M., Beck, J., West, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06331-w · Cited by 74
A Duplex CRISPR-Cas9 Ribonucleoprotein Nanomedicine for Colorectal Cancer Gene Therapy
Wan, T., Pan, Q., Liu, C., Guo, J., Li, B., Yan, X., Cheng, Y., & Ping, Y. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03708 · Cited by 73
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Self-citationMutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability
Galanos, P., Pappas, G., Polyzos, A., Kotsinas, A., Svolaki, I., Giakoumakis, N. N., Glytsou, C., Pateras, I. S., Swain, U., Souliotis, V. L., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1401-9 · Cited by 67
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000943 · Cited by 67
Jäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01118-x · Cited by 69
MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
Chen, X., Burkhardt, D. B., Hartman, A. A., Hu, X., Eastman, A. E., Sun, C., Wang, X., Zhong, M., Krishnaswamy, S., & Guo, S. (2019) · Nature Communications · doi:10.1038/s41467-019-13666-5 · Cited by 58
Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
Fenizia, F., Pasquale, R., Roma, C., Bergantino, F., Iannaccone, A., & Normanno, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.23 · Cited by 69
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
Ratnaparkhe, M., Hlevnjak, M., Kolb, T., Jauch, A., Maass, K. K., Devens, F., Rode, A., Hovestadt, V, Korshunov, A., Pastorczak, A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.55 · Cited by 63
Self-citationClonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis
Natarajan, P., Jaiswal, S., & Kathiresan, S. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001926 · Cited by 63
Oxidative damage to RPA limits the nucleotide excision repair capacity of human cells
Guven, M., Brem, R., Macpherson, P., Peacock, M., & Karran, P. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.255 · Cited by 61
Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61
De Angelis, M. L., Zeuner, A., Policicchio, E., Russo, G., Bruselles, A., Signore, M., Vitale, S., De Luca, G., Pilozzi, E., Boe, A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0214 · Cited by 60
Epigenetic landscape influences the liver cancer genome architecture
Hama, N., Totoki, Y., Miura, F., Tatsuno, K., Saito-Adachi, M., Nakamura, H., Arai, Y., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03999-y · Cited by 60
Self-citationGenomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma
Melamed, R. D., Aydin, I. T., Rajan, G. S., Phelps, R., Silvers, D. N., Emmett, K. J., Brunner, G., Rabadan, R., & Celebi, J. T. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.11.017 · Cited by 58
Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer
Narayan, S., Bader, G. D., & Reimand, J. (2016) · Genome Medicine · doi:10.1186/s13073-016-0311-2 · Cited by 54
“Such approaches are complicated by mutational heterogeneity, as mutation rates vary across genes, and nucleotide signatures [8, 10, 11], and are influenced by factors such as gene expression intensity [12], DNA replication timing [13], and chromatin organization [14].”
BackgroundGenomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58
Lodato, M. A., & Walsh, C. A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz191 · Cited by 56
Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?
Liebl, M. C., & Hofmann, T. G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15992 · Cited by 58
Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08108-9 · Cited by 54
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Keeping, S., Xu, Y., Chen, C.-I., Cope, S., Mojebi, A., Kuznik, A., Konidaris, G., Ayers, D., Sasane, M., Allen, R., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-0823 · Cited by 51
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
DNA polymerase η mutational signatures are found in a variety of different types of cancer
Rogozin, I. B., Goncearenco, A., Lada, A. G., De, S., Yurchenko, V., Nudelman, G., Panchenko, A. R., Cooper, D. N., & Pavlov, Y. I. (2018) · Cell Cycle · doi:10.1080/15384101.2017.1404208 · Cited by 39
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures
Li, R., Berglund, A., Zemp, L., Dhillon, J., Putney, R., Kim, Y., Jain, R. K., Grass, G. D., Conejo-Garcia, J., & Mulé, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694079 · Cited by 39
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Kossai, M., Radosevic-Robin, N., & Penault-Llorca, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100257 · Cited by 36
Rogozin, I. B., Lada, A. G., Goncearenco, A., Green, M. R., De, S., Nudelman, G., Panchenko, A. R., Koonin, E. V., & Pavlov, Y. I. (2016) · Scientific Reports · doi:10.1038/srep38133 · Cited by 33
Analyzing somatic mutations by single-cell whole-genome sequencing
Zhang, L., Lee, M., Maslov, A. Y., Montagna, C., Vijg, J., & Dong, X. (2024) · Nature Protocols · doi:10.1038/s41596-023-00914-8 · Cited by 26
Nucleosomes regulate base excision repair in chromatin
Meas, R., Wyrick, J. J., & Smerdon, M. J. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.10.002 · Cited by 28
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy
Couzinet, A., Suzuki, T., & Nakatsura, T. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2416975 · Cited by 27
DeepMF: deciphering the latent patterns in omics profiles with a deep learning method
Chen, L., Xu, J., & Li, S. C. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3291-6 · Cited by 23
Funingana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.008 · Cited by 23
The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Akhave, N. S., Biter, A. B., & Hong, D. S. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0356 · Cited by 17
Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma
Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-025-04178-x · Cited by 9
Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994
Fujihara, M., Sakata, R., Yoshida, N., Ozasa, K., Preston, D. L., & Mabuchi, K. (2022) · Blood · doi:10.1182/blood.2020010475 · Cited by 7
Immunotherapeutic strategies in breast cancer: a clinical update
Zhang, J. Q., & Plitas, G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26287 · Cited by 6
Yun, J., Youn, Y. C., & Kim, H. R. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.0086 · Cited by 6
Ren, P., Zheng, C., Pang, Y., Qiang, Y., Sun, S., Wang, Q., Xu, W., Lee, M., Lu, Z., Zhou, M., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-01011-z · Cited by 6
Wei, R., Dai, H., Zhang, J., Shih, D. J. H., Liang, Y., Xiao, P., McGrail, D. J., & Lin, S.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095008 · Cited by 4
Fan, N., Sun, Y., Yan, L., Chen, W., Wang, Y., Wang, S., & Song, Y. (2022) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-01048-y · Cited by 2
Sauty, S. M., Shine, J., Bostan, H., Li, J.-L., Mieczkowski, P. A., Loeser, R. F., Diekman, B. O., & Gordenin, D. A. (2026) · PLOS Genetics · doi:10.1371/journal.pgen.1012156
Metadata
- Authors
- Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Børresen-Dale, A.-L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjörd, J. E., Foekens, J. A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jäger, N., Jones, D. T. W., Jones, D., Knappskog, S., Kool, M., Lakhani, S. R., López-Otín, C., Martin, S., Munshi, N. C., Nakamura, H., Northcott, P. A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J. V., Puente, X. S., Raine, K., Ramakrishna, M., Richardson, A. L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T. N., Span, P. N., Teague, J. W., Totoki, Y., Tutt, A. N. J., Valdés-Mas, R., van Buuren, M. M., van ’t Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L. R., Zucman-Rossi, J., Andrew Futreal, P., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S. M., Siebert, R., Campo, E., Shibata, T., Pfister, S. M., Campbell, P. J., & Stratton, M. R.
- Affiliations
- Wellcome Sanger Institute (GB)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- Garvan Institute of Medical Research (AU)
- Lund University (SE)
- Oslo University Hospital (NO)
- Justus-Liebig-Universität Gießen (DE)
- Université Libre de Bruxelles (BE)
- German Cancer Research Center (DE)
- Erasmus MC Cancer Institute (NL)
- Inserm (FR)
- Broad Institute (US)
- The University of Queensland (AU)
- Universidad de Oviedo (ES)
- Harvard University (US)
- National Cancer Center Research Institute (JP)
- University of Glasgow (GB)
- Brigham and Women's Hospital (US)
- The Netherlands Cancer Institute (NL)
- Radboud University Medical Center (NL)
- King's College London (GB)
- Christian-Albrechts-Universität zu Kiel (DE)
- Corresponding author
- Stratton, Michael R.
- ORCID
- Alexandrov, Ludmil B.
- Wedge, David C.
- Aparicio, Samuel A. J. R.
- Behjati, Sam
- Biankin, Andrew V.
- Bolli, Niccolò
- Boyault, Sandrine
- Burkhardt, Birgit
- Caldas, Carlos
- Davies, Helen R.
- Desmedt, Christine
- Eils, Roland
- Hutter, Barbara
- Imbeaud, Sandrine
- Imielinski, Marcin
- Jäger, Natalie
- Knappskog, Stian
- Kool, Marcel
- Lakhani, Sunil R.
- Martin, Sancha
- Munshi, Nikhil C.
- Nakamura, Hiromi
- Northcott, Paul A.
- Pajic, Marina
- Papaemmanuil, Elli
- Paradiso, Angelo
- Pearson, John V.
- Raine, Keiran
- Ramakrishna, Manasa
- Richardson, Andrea L.
- Richter, Julia
- Rosenstiel, Philip
- Schlesner, Matthias
- Schumacher, Ton N.
- Span, Paul N.
- Teague, Jon W.
- Totoki, Yasushi
- Tutt, Andrew N. J.
- Waddell, Nicola
- Yates, Lucy R.
- McDermott, Ultan
- Meyerson, Matthew
- Grimmond, Sean M.
- Siebert, Reiner
- Shibata, Tatsuhiro
- Pfister, Stefan M.
- Campbell, Peter J.
- Stratton, Michael R.
- Venue
- Nature
- Published
- 2013-08-14
- Volume
- 500
- Issue
- 7463
- Pages
- 415-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3776390
- OpenAlex
- W2152061559
- Cited by
- 9,660
- References
- 67
- Citations by year
- 2026: 384 · 2025: 552 · 2024: 643 · 2023: 854 · 2022: 921 · 2021: 1119 · 2020: 1130 · 2019: 939 · 2018: 873 · 2017: 815 · 2016: 660 · 2015: 421 · 2014: 286 · 2013: 45
- FWCI
- 165.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-10-09)
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Deutsches Krebsforschungszentrum (69120)
- Wellcome Trust (088340, 093867, 098051)
- Broad Institute
- Canada's Michael Smith Genome Sciences Centre
- Cancer Research UK
- University of Glasgow
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Institut National de la Santé et de la Recherche Médicale
- University of New South Wales
- Lunds Universitet
- Universitetet i Oslo
- Háskóli Íslands
- Universitat de Barcelona
- BC Cancer Agency
- Labex Immuno-Oncology
- Medisinske fakultet, Universitetet i Oslo
- Cancer Research UK Cambridge Institute, University of Cambridge
- National Cancer Institute (T32CA009216)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- mutational signatures, somatic mutations, cancer genome, APOBEC cytidine deaminases, kataegis, hypermutation, patient age, cancer etiology, cancer types
- MeSH terms
- Aging, Algorithms, Cell Transformation, Neoplastic, Cytidine Deaminase, DNA, DNA Mutational Analysis, Humans, Models, Genetic, Mutagens, Mutation, Neoplasms, Organ Specificity, Transcription, Genetic, Reproducibility of Results, Mutagenesis, Insertional, Mutagenesis, Sequence Deletion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
